Akorn Inc. (AKRX) Stock Research, Analysis & News

Quick Analysis on Akorn Inc. (AKRX) Stock as of August 24, 2019

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Akorn Inc. (AKRX) Stock below)

Akorn Inc. (AKRX) Stock Profile Summary

Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States. The companys Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers. The companys Hospital Drugs & Injectables segment markets hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia; and other pharmaceutical products. This segment markets products to hospitals through the wholesale distribution channel. Its Contract Services segment manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers. The companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies. It has strategic partnerships with Strides Arcolab Limited; Serum Institute of India, Ltd.; Hameln Pharmaceuticals; and Cipla, Ltd. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.

Akorn Inc. (AKRX) Stock Key Statistics Research and Analysis as of August 24, 2019

Akorn Inc. (AKRX) Stock Competitor Research and Analysis

Alcon Inc. (ACL)Hospira Inc. (HSP)
Teva Pharmaceutical Industries Limited (TEVA)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Mutual Funds with Akorn Inc. (AKRX) Stock in its top 10 holdings

FundCategoryAKRX Holding Percentage
LKCM Aquinas Small CapSmall Growth2.2%
LKCM Small Cap Equity AdvisorSmall Growth2.11%

ETFs with Akorn Inc. (AKRX) Stock in its top 10 holdings

Stock Research on Akorn Inc. (AKRX)

Latest Market News on Akorn Inc. (AKRX)


Click here to find the latest news on Akorn Inc. (AKRX)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Alcon Inc. (ACL)
Hospira Inc. (HSP)
Teva Pharmaceutical Industries Limited (TEVA)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)